A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)

Launched by MERCK SHARP & DOHME LLC · Mar 12, 2025

Keywords

ClinConnect Summary

The clinical trial titled "A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants" is researching how different forms of a medication called enlicitide behave in the body of healthy adults. The main goal is to understand how the body absorbs and processes enlicitide over time when given in various forms. This information will help researchers learn which formulation might be the most effective.

To participate in this study, individuals must be healthy, between the ages of 18 to 65 years old, and have a body mass index (BMI) between 18 and 32. Additionally, participants should not smoke or have used any tobacco products for at least three months. Those with certain health issues, like gastrointestinal diseases or a history of cancer, may not be eligible. If you join the trial, you can expect to take the medication in one of its formulations and be monitored over time to see how your body reacts. This study is currently recruiting participants, and your involvement could contribute to important research on this medication.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The main inclusion criteria include but are not limited to the following:
• • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior
• • Has body mass index (BMI) ≥18 kg/m\^2 and ≤32 kg/m\^2
• Exclusion Criteria:
• The main exclusion criteria include but are not limited to the following:
• • Has history of gastrointestinal disease which may affect food and drug absorption or has had a gastric bypass or similar surgery
• • Has history of cancer (malignancy)
• • Has positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV)